Confronto
Cetrorelix vs. Humanin
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
120287-85-6
330936-69-1
Peso molecolare
1431.06 g/mol
2687.27 g/mol
Emivita
nessun dato
nessun dato
Sequenza
nessun dato
Met-Ala-Pro-Arg-Gly-Phe-Ser-Cys-Leu-Leu-Leu-Leu-Thr-Ser-Glu-Ile-Asp-Leu-Pro-Val-Lys-Arg-Arg-AlaMeccanismo d'azione
Cetrorelix
Cetrorelix competitively and immediately blocks the pituitary GnRH receptor, rapidly suppressing LH and FSH release — without the initial hormone surge ('flare') of GnRH agonists.
Humanin
Humanin arises from a short open reading frame within the 16S rRNA region of the mitochondrial genome (MT-RNR2) — it is therefore not encoded by nuclear DNA. Mechanistically, preclinical work describes a cytoprotective, anti-apoptotic effect via multiple pathways: an extracellular interaction with a trimeric receptor complex of gp130, CNTFR and WSX-1 with downstream activation of JAK2/STAT3 signalling, as well as intracellular interactions including inhibition of the pro-apoptotic protein BAX (and of tBID), binding to IGFBP-3 with modulation of the IGF-1 axis, and interaction with FPRL1/FPRL2 receptors. These models derive predominantly from cell culture and rodents; the extent to which they reflect human physiology after administration of exogenous synthetic humanin is not established by controlled human trials.
Base di evidenze
Evidenza più alta
RCT sull'uomo
Studio sull'uomo
Studi
0
4
di cui sull'uomo
0
1
Effetti registrati
2
4
Contraddizioni aperte
0
1
Eventi avversi documentati
1
0
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Cetrorelix and Humanin?
- Cetrorelix is classified as "Ricerca (altro)", while Humanin is classified as "Ricerca (altro)". Cetrorelix: Cetrorelix is a synthetic decapeptide and GnRH antagonist. It is used in assisted reproduction (IVF) to prevent a premature LH surge during controlled ovarian stimulation. Humanin: Humanin is a 24-amino-acid mitochondrial-encoded peptide (mitochondrial-derived peptide, MDP) whose open reading frame lies within the 16S rRNA region (gene MT-RNR2) of mitochondrial DNA. It is considered the founding member of the MDP family and was discovered in 2001 by the Hashimoto/Nishimoto group while searching for neuroprotective factors in the brain of an Alzheimer's patient. In basic research (including the laboratory of Pinchas Cohen) humanin is described as a cytoprotective, anti-apoptotic peptide and is studied in the contexts of Alzheimer's/neuroprotection, metabolism/insulin action and aging. The evidence comes almost entirely from cell and animal models and from observations of endogenous levels in humans; controlled human trials of exogenous humanin as a therapeutic are lacking. It is not approved as a medicine anywhere and is traded on the grey market as a research chemical. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Cetrorelix or Humanin?
- The highest available evidence level is "RCT sull'uomo" for Cetrorelix and "Studio sull'uomo" for Humanin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Cetrorelix and Humanin in Germany and the United States?
- Germania: Cetrorelix — Su prescrizione, Humanin — Non approvato. Stati Uniti: Cetrorelix — Su prescrizione, Humanin — Solo ricerca. These are factual summaries with source and review date on the individual pages.